Travere Therapeutics (TVTX) EBITDA (2011 - 2026)
Travere Therapeutics' (TVTX) quarterly EBITDA came in at -$36.9 million in Q1 2026, up 13.5% YoY from -$32.5 million in Q1 2025, and down 13.84% on a QoQ basis from -$32.4 million in Q4 2025.
Travere Therapeutics (TVTX) EBITDA (2011 - 2026) Analysis & Trends
Travere Therapeutics (TVTX) has 16 years of EBITDA data on file, last reported at -$36.9 million in Q1 2026.
- Quarterly EBITDA rose 13.5% year-over-year to -$36.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$57.1 million (up 74.89% YoY) and the FY2025 annual result came in at -$62.8 million, up 80.6% from the prior year.
- EBITDA retreated to -$36.9 million in Q1 2026, from -$32.4 million in the prior quarter.
- In the past five years, EBITDA ranged from a high of $24.9 million in Q3 2025 to a low of -$139.2 million in Q1 2024.
- A 5-year average of -$66.6 million and a median of -$72.0 million in 2022 frame the typical range for EBITDA.
- Annual changes were most pronounced in 2022 — EBITDA tumbled 160.49% — and 2025, when it surged 144.4%.
- Tracing TVTX's EBITDA over 5 years: stood at -$86.7 million in 2022, then slipped by 8.69% to -$94.2 million in 2023, then soared by 35.55% to -$60.7 million in 2024, then soared by 46.61% to -$32.4 million in 2025, then dropped by 13.84% to -$36.9 million in 2026.
- The last three EBITDA figures came in at -$36.9 million (Q1 2026), -$32.4 million (Q4 2025), and $24.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Travere Therapeutics | 5.85 Bn | 5.85 Bn | 162.52 Mn | 3.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.95 Mn |
| Mar 31, 2026 | -36.92 Mn |
| Dec 31, 2025 | -32.43 Mn |
| Sep 30, 2025 | 24.93 Mn |
| Jun 30, 2025 | -12.65 Mn |
| Mar 31, 2025 | -42.67 Mn |
| Dec 31, 2024 | -60.74 Mn |
| Sep 30, 2024 | -56.15 Mn |
| Jun 30, 2024 | -67.70 Mn |
| Mar 31, 2024 | -139.24 Mn |
| Dec 31, 2023 | -94.23 Mn |
| Sep 30, 2023 | -92.59 Mn |
| Jun 30, 2023 | -103.95 Mn |
| Mar 31, 2023 | -97.37 Mn |
| Dec 31, 2022 | -86.70 Mn |
| Sep 30, 2022 | -82.60 Mn |
| Jun 30, 2022 | -78.53 Mn |
| Mar 31, 2022 | -71.98 Mn |
| Dec 31, 2021 | -84.85 Mn |
| Sep 30, 2021 | -31.71 Mn |